• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by EyePoint Pharmaceuticals Inc. (Amendment)

    12/8/23 5:28:55 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $EYPT alert in real time by email
    SC 13D/A 1 d884875dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)*

     

     

    EyePoint Pharmaceuticals, Inc.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    30233G100

    (CUSIP Number)

    Ronald W. Eastman

    EW Healthcare Partners L.P.

    21 Waterway Avenue, Suite 225

    The Woodlands, Texas 77380

    (281) 364-1555

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    December 4, 2023

    (Date of Event which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


      1    

      NAME OF REPORTING PERSON

      S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

      EW Healthcare Partners L.P.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS

     

      WC

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

      2,247,432 (1)

         8  

      SHARED VOTING POWER

     

      -0-

         9  

      SOLE DISPOSITIVE POWER

     

      2,247,432 (1)

       10  

      SHARED DISPOSITIVE POWER

     

      -0-

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,247,432 (1)

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      4.8%

    14  

      TYPE OF REPORTING PERSON

     

      PN

     

    (1)

    See Item 5.


      1    

      NAME OF REPORTING PERSON

      S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

      EW Healthcare Partners-A L.P.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS

     

      WC

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

      90,354 (1)

         8  

      SHARED VOTING POWER

     

      -0-

         9  

      SOLE DISPOSITIVE POWER

     

      90,354 (1)

       10  

      SHARED DISPOSITIVE POWER

     

      -0-

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      90,354 (1)

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      0.2%

    14  

      TYPE OF REPORTING PERSON

     

      PN

     

    (1)

    See Item 5.


      1    

      NAME OF REPORTING PERSON

      S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

      Essex Woodlands Fund IX-GP, L.P.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS

     

      OO

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

      2,337,786 (1)

         8  

      SHARED VOTING POWER

     

      -0-

         9  

      SOLE DISPOSITIVE POWER

     

      2,337,786 (1)

       10  

      SHARED DISPOSITIVE POWER

     

      -0-

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,337,786 (1)

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      5.0%

    14  

      TYPE OF REPORTING PERSON

     

      PN

     

    (1)

    See Item 5.


      1    

      NAME OF REPORTING PERSON

      S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

      Essex Woodlands IX, LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS

     

      OO

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      2,337,786 (1)

         8   

      SHARED VOTING POWER

     

      -0-

         9   

      SOLE DISPOSITIVE POWER

     

      2,337,786 (1)

       10   

      SHARED DISPOSITIVE POWER

     

      -0-

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,337,786 (1)

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      5.0%

    14  

      TYPE OF REPORTING PERSON

     

      OO

     

    (1)

    See Item 5.


      1    

      NAME OF REPORTING PERSON

      S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

      Martin P. Sutter

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS

     

      OO

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      -0-

         8   

      SHARED VOTING POWER

     

      2,337,786 (1)

         9   

      SOLE DISPOSITIVE POWER

     

      -0-

       10   

      SHARED DISPOSITIVE POWER

     

      2,337,786 (1)

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,337,786 (1)

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      5.0%

    14  

      TYPE OF REPORTING PERSON

     

      IN

     

    (1)

    See Item 5.


      1    

      NAME OF REPORTING PERSON

      S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

      R. Scott Barry

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS

     

      OO

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      -0-

         8   

      SHARED VOTING POWER

     

      2,337,786 (1)

         9   

      SOLE DISPOSITIVE POWER

     

      -0-

       10   

      SHARED DISPOSITIVE POWER

     

      2,337,786 (1)

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,337,786 (1)

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      5.0%

    14  

      TYPE OF REPORTING PERSON

     

      IN

     

    (1)

    See Item 5.


      1    

      NAME OF REPORTING PERSON

      S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

      Ronald Eastman

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS

     

      OO

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

      -0-

         8  

      SHARED VOTING POWER

     

      2,337,786 (1)

         9  

      SOLE DISPOSITIVE POWER

     

      -0-

       10  

      SHARED DISPOSITIVE POWER

     

      2,337,786 (1)

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,337,786 (1)

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      5.0%

    14  

      TYPE OF REPORTING PERSON

     

      IN

     

    (1)

    See Item 5.


      1    

      NAME OF REPORTING PERSON

      S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

      Petri Vainio

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS

     

      OO

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

      -0-

         8  

      SHARED VOTING POWER

     

      2,337,786 (1)

         9  

      SOLE DISPOSITIVE POWER

     

      -0-

       10  

      SHARED DISPOSITIVE POWER

     

      2,337,786 (1)

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,337,786 (1)

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      5.0%

    14  

      TYPE OF REPORTING PERSON

     

      IN

     

    (1)

    See Item 5.


      1    

      NAME OF REPORTING PERSON

      S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

      Steve Wiggins

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS

     

      OO

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

      -0-

         8  

      SHARED VOTING POWER

     

      2,337,786 (1)

         9  

      SOLE DISPOSITIVE POWER

     

      -0-

       10  

      SHARED DISPOSITIVE POWER

     

      2,337,786 (1)

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,337,786 (1)

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      5.0%

    14  

      TYPE OF REPORTING PERSON

     

      IN

     

    (1)

    See Item 5.


    SCHEDULE 13D

     

    Item 1.

    Security and Issuer.

    This Amendment No. 4 to Schedule 13D (“Amendment No. 4”) amends and supplements the Schedule 13D filed on April 10, 2018, as amended and supplemented by Amendment No. 1 thereto filed July 15, 2018, Amendment No. 2 thereto filed February 13, 2019 and Amendment No. 3 filed August 30, 2023 (as amended, the “Amended Schedule 13D”), and relates to the Reporting Persons’ beneficial ownership of shares of the common stock, par value $0.001 per share (the “Common Stock”), of EyePoint Pharmaceuticals, Inc. (the “Issuer”). Only those items that are hereby reported are amended; all other items reported in the Amended Schedule 13D remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment No. 4 have the meanings ascribed to them in the Amended Schedule 13D. This Amendment No. 4 is being filed to reflect the sales of shares of Common Stock of the Issuer by the Reporting Persons that occurred between December 4, 2023 and December 6, 2023, as well as to reflect the issuance of shares of Common Stock by the Issuer to third parties in the Company Offering as described in Item 5 below.

    (a) Name of Issuer: EyePoint Pharmaceuticals, Inc. (formerly known as pSivida Corp.)

    (b) Address of Issuer’s Principal Executive Offices:

    480 Pleasant Street

    Watertown, Massachusetts 02472

    (c) Title and Class of Securities: Common Stock

    (d) CUSIP Number: 30233G100

     

    Item 2.

    Identity and Background.

    (a) This Amendment No. 4 is being filed jointly by EW Healthcare Partners L.P., a Delaware limited partnership (“EWHP”), EW Healthcare Partners-A L.P., a Delaware limited partnership (“EWHP-A”), Essex Woodlands Fund IX-GP, L.P., a Delaware limited partnership ( “Essex IX Fund GP”), Essex Woodlands IX, LLC, a Delaware limited liability company (“Essex IX General Partner”), Martin P. Sutter, an individual, R. Scott Barry, an individual, Ronald Eastman, an individual, Petri Vainio, an individual, and Steve Wiggins, an individual (each a “Manager”, collectively, the “Managers”, and together with the EWHP, EWHP-A, Essex IX Fund GP and the Essex IX General Partner, the “Reporting Persons”).

    (b) Address of Principal Business Office: The address of the principal business of each of the Reporting Persons is 21 Waterway Avenue, Suite 225, The Woodlands, Texas 77380.

    (c) The Principal business of EWHP and EWHP-A is growth capital investments. The principal business of Essex IX Fund GP is to act as the general partner of EWHP and EWHP-A. The principal business of Essex IX General Partner is to act as the general partner of Essex IX Fund GP. The principal business of the Managers is to direct the activities of Essex IX General Partner.

    (d) None of the Reporting Persons have, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

    (e) None of the Reporting Persons have, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which such person was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

    (f) Citizenship: (i) EWHP is a Delaware limited partnership; (ii) EWHP-A is a Delaware limited partnership; (iii) Essex IX Fund GP is a Delaware limited partnership; (iv) Essex IX General Partner is a Delaware limited liability company; (v) the Managers are all individuals who are citizens of the United States.


    Item 4.

    Purpose of Transaction

    The Reporting Persons disposed of the Securities described in Item 5 for liquidity and market purposes. Depending upon overall market conditions, other investment opportunities available to the Reporting Persons, and the availability of Securities at prices that would make the purchase or sale of Securities desirable, the Reporting Persons may endeavor to increase or decrease their position in the Issuer through, among other things, the purchase or sale of Securities on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Persons may deem advisable. Except for the above, none of the Reporting Persons has any present plan or proposal which relates to, or could result in, any of the events referred to in paragraphs (a) through (j), inclusive, of Item 4 of Schedule 13D. However, the Reporting Persons will continue to review the business of the Issuer and, depending upon one or more of the factors referred to above, may in the future propose that the Issuer take one or more such actions.

     

    Item 5.

    Interest in Securities of the Issuer

    TOTAL OUTSTANDING SHARES. According to information set forth in the Issuer’s final prospectus on Form 424(b)(5) filed with the Securities and Exchange Commission on December 6, 2023, the number of shares of the Issuer’s Common Stock outstanding immediately following the consummation of the Company Offering was 47,074,138 shares.

    EWHP INVESTORS. As of the date of this Amendment No. 4, the Reporting Persons may be deemed to beneficially own, for purposes of Rule 13D-3(d)(1)(i) of the Act, an aggregate 2,337,786 shares of Common Stock (the “Securities”), which represents approximately 5.0% of the Common Stock outstanding. The Securities include 2,247,432 shares held by EWHP and 90,354 shares held by EWHP-A. The Reporting Persons did not, and do not, have the right to acquire any additional shares of Common Stock within sixty days of the date of this Amendment No. 4. EWHP and EWHP-A have the sole voting and investment power with respect to their respective Securities.

    During the last sixty (60) days, the Reporting Persons effected the following transactions in the Issuer’s Common Stock:

     

    DATE    REPORTING PERSON    AMOUNT      PRICE   TYPE OF TRANSACTION

    12/4/2023

       EWHP      112,643      $20.01(1)   Open market sale

    12/4/2023

       EWHP-A      4,534      $20.01(1)   Open market sale

    12/4/2023

       EWHP      83,883      $22.04(2)   Open market sale

    12/4/2023

       EWHP-A      3,377      $22.04(2)   Open market sale

    12/5/2023

       EWHP      287,138      $20.14(3)   Open market sale

    12/5/2023

       EWHP-A      11,560      $20.14(3)   Open market sale

    12/6/2023

       EWHP      541,916      $20.17(4)   Open market sale

    12/6/2023

       EWHP-A      21,835      $20.17(4)   Open market sale

    12/6/2023

       EWHP      82,909      $20.69(5)   Open market sale

    12/6/2023

       EWHP-A      3,340      $20.69(5)   Open market sale

     

    (1)

    Price is the volume weighted average selling price of all sales by the Reporting Persons on the transaction date within a one dollar range. Actual prices ranged from $20.00 to $20.29. The Reporting Persons hereby undertake to provide upon request of the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

    (2)

    Price is the volume weighted average selling price of all sales by the Reporting Persons on the transaction date within a one dollar range. Actual prices ranged from $22.00 to $22.44. The Reporting Persons hereby undertake to provide upon request of the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

    (3)

    Price is the volume weighted average selling price of all sales by the Reporting Persons on the transaction date within a one dollar range. Actual prices ranged from $20.00 to $20.53. The Reporting Persons hereby undertake to provide upon request of the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.


    (4)

    Price is the volume weighted average selling price of all sales by the Reporting Persons on the transaction date within a one dollar range. Actual prices ranged from $19.57 to $20.56. The Reporting Persons hereby undertake to provide upon request of the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

    (5)

    Price is the volume weighted average selling price of all sales by the Reporting Persons on the transaction date within a one dollar range. Actual prices ranged from $20.57 to $20.86. The Reporting Persons hereby undertake to provide upon request of the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

    Rule 13d-2(a) under the Act provides that if any material change occurs in the facts set forth in a reporting person’s Schedule 13D, including any material increase or decrease in the percentage of the class beneficially owned, such reporting person promptly shall file an amendment to such Schedule 13D. Rule 13d-2(a) further provides that an acquisition or disposition of securities in an amount equal to one percent (1%) or more of the class of securities shall be deemed “material” for purposes of the foregoing amendment requirement.

    On December 8, 2023, the Issuer completed an offering of Securities (the “Company Offering”), which resulted in the ownership percentage of the Securities held by the Reporting Persons to be reduced by one percent (1%) or more of the Securities then outstanding. This Amendment No. 4 is being filed to, among other things, reflect and report such changes to such ownership percentages to the Securities held by the Reporting Persons as a result of the Company Offering, including the sixty (60)-day pre-amendment trading history required by Item 5(c) of Schedule 13D.

     

    COMPANY

    OFFERING DATE

       SHARES
    SOLD/ISSUED
       COMPANY
    SHARES
    OUTSTANDING
       REPORTING
    PERSONS
       AMOUNT
    BENEFICIALLY
    OWNED
       PERCENT
    OF
    CLASS
       CHANGE IN
    PERCENT OF
    CLASS FROM
    PREVIOUS
    12/8/2023    11,764,706    47,074,138    EWHP    2,247,432    4.8%    -5.3%
             EWHP-A    90,354    0.2%    -0.2%
             Essex IX Fund GP    2,337,786    5.0%    -5.5%
             Essex IX General
    Partner
       2,337,786    5.0%    -5.5%
             Managers    2,337,786    5.0%    -5.5%

    The share totals and ownership percentages reported by the Reporting Persons in this Amendment No. 4 are reflective of the Company Offering.

    The filing of this Amendment No. 4 represents the final amendment to Amended Schedule 13D and constitutes an exit filing for the Reporting Persons.

     

    Item 7.

    Material to be filed as Exhibits

     

    Exhibit 1:    Joint Filing Agreement, dated December 8, 2023.
    Exhibit 2:    Voting and Investors Rights Agreement, dated December  31, 2020, by and among the Issuer, Ocumension Therapeutics, EW Healthcare Partners LP and EW Healthcare Partners -A LP (incorporated by reference to Exhibit 10.35 to the Issuer’s Annual Report on Form 10-K filed on March 10, 2023).


    Signatures

    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

    Date: December 8, 2023

     

    EW HEALTHCARE PARTNERS L.P.                  INDIVIDUALS:
    By:  

    Essex Woodlands Fund IX-GP, L.P.,

    Its General Partner

       
    By:   Essex Woodlands IX, LLC,    

    /s/ Martin P. Sutter

      Its General Partner     Name: Martin P. Sutter
    By:  

    /s/ Ronald W. Eastman

       

    /s/ R. Scott Barry

      Name:   Ronald W. Eastman     Name: R. Scott Barry
      Title:   Manager    

    EW HEALTHCARE PARTNERS-A L.P.

     

    By:   Essex Woodlands Fund IX-GP, L.P.,                 

    /s/ Ronald W. Eastman

      Its General Partner     Name: Ronald W. Eastman
    By:   Essex Woodlands IX, LLC,    
      Its General Partner    
    By:  

    /s/ Ronald W. Eastman

       

    /s/ Petri Vainio

      Name:   Ronald W. Eastman     Name: Petri Vainio
      Title:   Manager    
           

    /s/ Steve Wiggins

            Name: Steve Wiggins

    ESSEX WOODLANDS FUND IX-GP, L.P.

     

    By:   Essex Woodlands IX, LLC,
      Its General Partner
    By:  

    /s/ Ronald W. Eastman

      Name:   Ronald W. Eastman
      Title:   Manager
    ESSEX WOODLANDS IX, LLC

    /s/ Ronald W. Eastman

    Name:Ronald W. Eastman
    Title:Manager
    Get the next $EYPT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EYPT

    DatePrice TargetRatingAnalyst
    6/17/2025$28.00Outperform
    RBC Capital Mkts
    1/7/2025$33.00Buy
    Citigroup
    10/16/2024Sector Outperform
    Scotiabank
    8/28/2024$15.00Buy
    Jefferies
    1/22/2024$35.00Overweight
    JP Morgan
    11/2/2023$20.00Buy
    Mizuho
    4/21/2023$33.00Outperform
    Robert W. Baird
    7/7/2022$21.00Buy
    Chardan Capital Markets
    More analyst ratings

    $EYPT
    SEC Filings

    View All

    EyePoint Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - EyePoint, Inc. (0001314102) (Filer)

    1/7/26 7:05:26 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 8-K filed by EyePoint Pharmaceuticals Inc.

    8-K - EyePoint Pharmaceuticals, Inc. (0001314102) (Filer)

    12/8/25 9:49:43 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 144 filed by EyePoint Pharmaceuticals Inc.

    144 - EyePoint Pharmaceuticals, Inc. (0001314102) (Subject)

    12/4/25 10:24:55 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $EYPT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

    WATERTOWN, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that George O. Elston, Executive Vice President and Chief Financial Officer of EyePoint, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 11:00 am ET. A webcast and subsequent archived replay of the fireside chat may be accessed via the Investors section of the Company website at www.eyepoint.bio. About EyePoint EyePoint, Inc. (NASDAQ:EYPT) is a clinical-stage biopharmaceutic

    2/5/26 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    WATERTOWN, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 13,900 shares of EyePoint common stock to three new employees. The stock options were granted on January 15, 2026. The grants were approved by the Compensation Committee and made as an inducement mater

    1/16/26 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026

    – Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets – – Pivotal Phase 3 trials in wet AMD on track for data readout beginning in mid-2026 – – Phase 3 DME program first patient dosing expected in Q1 2026 – – Presenting at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 7:30 a.m. PT – WATERTOWN, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today reported a corporate update and anticipated 2026 pivotal milesto

    1/7/26 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $EYPT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lurker Nancy converted options into 75,133 shares, increasing direct ownership by 34% to 294,346 units (SEC Form 4)

    4 - EyePoint, Inc. (0001314102) (Issuer)

    1/7/26 4:13:32 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    President and CEO Duker Jay S. converted options into 20,793 shares and covered exercise/tax liability with 10,054 shares, increasing direct ownership by 16% to 77,752 units (SEC Form 4)

    4 - EyePoint, Inc. (0001314102) (Issuer)

    1/7/26 4:12:52 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Chief Financial Officer Elston George converted options into 15,285 shares and covered exercise/tax liability with 4,487 shares, increasing direct ownership by 13% to 91,852 units (SEC Form 4)

    4 - EyePoint, Inc. (0001314102) (Issuer)

    1/7/26 4:12:02 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $EYPT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on EyePoint Pharmaceuticals with a new price target

    RBC Capital Mkts initiated coverage of EyePoint Pharmaceuticals with a rating of Outperform and set a new price target of $28.00

    6/17/25 7:49:38 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Citigroup initiated coverage on EyePoint Pharmaceuticals with a new price target

    Citigroup initiated coverage of EyePoint Pharmaceuticals with a rating of Buy and set a new price target of $33.00

    1/7/25 7:52:05 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Scotiabank initiated coverage on EyePoint Pharmaceuticals

    Scotiabank initiated coverage of EyePoint Pharmaceuticals with a rating of Sector Outperform

    10/16/24 8:38:45 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $EYPT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Zaderej Karen L. bought $59,000 worth of shares (10,000 units at $5.90), increasing direct ownership by 38% to 36,500 units (SEC Form 4)

    4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)

    5/19/25 4:06:14 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Zaderej Karen L. bought $54,450 worth of shares (10,000 units at $5.45), increasing direct ownership by 61% to 26,500 units (SEC Form 4)

    4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)

    5/15/25 4:06:14 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Dicicco Wendy F bought $19,997 worth of shares (2,567 units at $7.79), increasing direct ownership by 35% to 9,967 units (SEC Form 4)

    4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)

    8/21/24 4:32:51 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $EYPT
    Leadership Updates

    Live Leadership Updates

    View All

    EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors

    WATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of Reginald J. Sanders, M.D., FASRS, a distinguished leader in ophthalmology, to its Board of Directors. "I am pleased to welcome Dr. Sanders to EyePoint's Board," said Göran Ando, M.D., Chair of the Board of Directors of EyePoint. "Scientific and medical leadership underpin our mission to develop innovative therapeutics for patients with serious retinal diseases, and as a prominent leader in the retina community, Dr. San

    1/8/25 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors

    WATERTOWN, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of Fred Hassan, a distinguished industry leader to its Board of Directors. "I am honored to welcome Fred Hassan to EyePoint's Board," said Göran Ando, M.D., Chair of the Board of Directors of EyePoint Pharmaceuticals. "He joins at an important time for the Company as we approach first patient dosing for the pivotal Phase 3 LUGANO trial of DURAVYU™ in wet age-related macular degeneration (AMD) and as we prepare for future

    9/4/24 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists

    - Charles Wykoff, M.D., Ph.D. joins Carl Regillo, M.D., FACS as co-chair of Scientific Advisory Board – - Usha Chakravarthy, M.B.B.S, PhD., Allen Ho, M.D. FACS FASRS and Frank Holz, M.D., F.E.B.O, F.A.R.V.O join in advance of global Phase 3 clinical trials for EYP-1901(DURAVYU) in wet AMD – - Company on track to initiate the first Phase 3 pivotal trial (LUGANO) for DURYVU in wet AMD in 2H 2024 - WATERTOWN, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of leading global ophthalmologists

    4/2/24 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $EYPT
    Financials

    Live finance-specific insights

    View All

    EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025

    WATERTOWN, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 5, 2025 to report its third quarter 2025 financial results and highlight recent corporate developments. To access the live conference call, please register using the audio conference link: https://edge.media-server.com/mmc/p/fgkir3sg. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepointpharm

    10/29/25 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments

    – Completed Phase 3 enrollment for DURAVYU™ in wet AMD with over 800 patients enrolled and randomized – – LUGANO and LUCIA trials each rapidly enrolled in seven months underscoring strong physician and patient interest – – Topline 56-week data for LUGANO on track for readout in mid-2026 with LUCIA topline data to closely follow – – Northbridge, MA commercial manufacturing facility on line with DURAVYU registration batches underway – – $256 million of cash, cash equivalents and marketable securities as of June 30, 2025, provides cash runway into 2027, beyond topline data for both Phase 3 wet AMD trials – WATERTOWN, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuti

    8/6/25 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025

    WATERTOWN, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, August 6, 2025 to report its second quarter 2025 financial results and highlight recent corporate developments. To access the live conference call, please register using the audio conference link: https://register-conf.media-server.com/register/BI2f02d8b4966b40da83f2ef4135b2ba78. A live audio webcast of the event can be accessed via the Investors section of the

    7/30/25 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $EYPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by EyePoint Pharmaceuticals Inc.

    SC 13G/A - EyePoint Pharmaceuticals, Inc. (0001314102) (Subject)

    11/14/24 3:10:08 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by EyePoint Pharmaceuticals Inc.

    SC 13G/A - EyePoint Pharmaceuticals, Inc. (0001314102) (Subject)

    11/14/24 1:22:34 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by EyePoint Pharmaceuticals Inc.

    SC 13G/A - EyePoint Pharmaceuticals, Inc. (0001314102) (Subject)

    11/12/24 2:31:58 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials